**Supplementary Table 1. Excluded studies.**

|  |  |  |
| --- | --- | --- |
| **Publication** | **Search Term** | **Reason for Exclusion** |
| Gani et al, 19971 | Formulation of azelastine hydrochloride and fluticasone propionate | Not in English/Review |
| Med Lett Drugs Ther, 20122 | Dymista | Review/Unrelated |
| Meltzer et al, 20123 | MP29-02 | Only including pooled analysis of multicenter studies |
| Berger, 20134 | MP29-02 | Review |
| Bernstein, 20135 | MP29-02 | Review |
| Klimek et al, 20136 | MP29-02 | Not in English |
| Derendorf et al, 20147 | MP29-02 | Review |
| Devillier et al, 20148 | MP29-02 | Unrelated |
| Drug Therapy Bulletin, 20149 | Dymista | Unrelated |
| Harrow et al, 201410 | Dymista | Economic model |
| Berger et al, 201511 | MP-AzeFlu | Review |
| Bousquet et al, 201512 | MP29-02 | Review |
| Ridolo et al, 201513 | MP29-02 | Review |
| Rossi et al, 201514 | MP29-02 | Unrelated |
| Brixner et al, 201615 | MP-AzeFlu | Unrelated |
| Harrow et al, 201616 | MP-AzeFlu | Unrelated |
| Klimek et al, 201617 | MP-AzeFlu | Review |
| Klimek et al, 201618 | MP-AzeFlu | Unrelated |
| Klimek et al, 201619 | MP29-02 | Review |
| Prenner, 201620 | MP-AzeFlu | Review |
| Dollner et al, 201721 | MP-AzeFlu | Only including pooled analysis of multicenter studies |
| Lipworth et al, 201722 | Dymista | Consensus statement |
| Scadding et al, 201723 | MP-AzeFlu | Only including pooled analysis of multicenter studies |
| Agache et al, 201824 | MP-AzeFlu | Only including pooled analysis of multicenter studies |
| Bachert et al, 201825 | MP-AzeFlu | Unrelated |
| Häussler et al, 201826 | MP29-02 | In vitro study |
| Kaulsay et al, 201827 | MP-AzeFlu | Only including pooled analysis of multicenter studies |
| Morse et al, 201828 | Dymista | Unrelated |
| Roca-Ferrer et al, 201829 | MP-AzeFlu | In vitro study |
| Bjermer et al, 201930 | MP-AzeFlu | Unrelated |
| Haahr et al, 201931 | MP-AzeFlu | Only including pooled analysis of multicenter studies |
| Ilyina et al, 201932 | MP-AzeFlu | Only including pooled analysis of multicenter studies |
| Klimek et al, 201933 | MP29-02 | Review |
| Scadding et al, 201934 | MP-AzeFlu | Unrelated |
| Stjarne et al, 201935 | MP-AzeFlu | Only including pooled analysis of multicenter studies |

iTNSS, instantaneous total nasal symptom score; rTNSS, reflective total nasal symptom score; VAS, visual analogue scale

**References**

1. Gani F, Senna G, Crivellaro M, Dama A, Castellani L and Mezzelani P. [New drugs in the treatment of respiratory allergic diseases]. *Recenti Prog Med*. 1997; 88: 333-41.

2. Azelastine/fluticasone propionate(Dymista) for seasonal allergic rhinitis. *Med Lett Drugs Ther*. 2012; 54: 85-7.

3. Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D and Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. *Allergy Asthma Proc*. 2012; 33: 324-32.

4. Berger WE. MP29-02 for the treatment of seasonal allergic rhinitis: a review of clinical pharmacology, efficacy and safety. *Expert Rev Clin Immunol*. 2013; 9: 803-11.

5. Bernstein JA. MP29-02: a breakthrough for the treatment of allergic rhinitis. *Expert Opin Pharmacother*. 2013; 14: 2101-13.

6. Klimek L and Sperl A. [Evidence-based treatment options for allergic diseases in otolaryngology: an update]. *HNO*. 2013; 61: 525-38.

7. Derendorf H, Meltzer EO, Hermann R and Canonica GW. Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. *Drugs Today (Barc)*. 2014; 50: 15-31.

8. Devillier P, Dreyfus JF, Demoly P and Calderon MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. *BMC Med*. 2014; 12: 71.

9. Azelastine and fluticasone nasal spray: any advantage? *Drug Ther Bull*. 2014; 52: 21-4.

10. Harrow B, Hofmeister J, Gever LN, et al. Can Improved Treatment of Allergic Rhinitis Improve Workplace Productivity? The Role of Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate (Dymista). *Value Health*. 2014; 17: A598.

11. Berger WE and Meltzer EO. Intranasal spray medications for maintenance therapy of allergic rhinitis. *Am J Rhinol Allergy*. 2015; 29: 273-82.

12. Bousquet J, Bachert C, Bernstein J, et al. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. *Expert Opin Pharmacother*. 2015; 16: 913-28.

13. Ridolo E, Montagni M, Melli V, Bonzano L, Incorvaia C and Canonica GW. A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis. *Ther Deliv*. 2015; 6: 653-9.

14. Rossi O, Massaro I, Caminati M, et al. Escaping the trap of allergic rhinitis. *Clin Mol Allergy*. 2015; 13: 17.

15. Brixner D, Meltzer EO, Morland K, Carroll CA, Munzel U and Lipworth BJ. Implication of Alternative Minimal Clinically Important Difference Threshold Estimation Methods on Technology Assessment. *Int J Technol Assess Health Care*. 2016; 32: 371-5.

16. Harrow B, Sedaghat AR, Caldwell-Tarr A and Dufour R. A Comparison of Health Care Resource Utilization and Costs for Patients with Allergic Rhinitis on Single-Product or Free-Combination Therapy of Intranasal Steroids and Intranasal Antihistamines. *J Manag Care Spec Pharm*. 2016; 22: 1426-36.

17. Klimek L, Demoly P and Price D. Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu. *Expert Rev Clin Pharmacol*. 2016; 9: 705-14.

18. Klimek L, Mullol J, Hellings P, Gevaert P, Mosges R and Fokkens W. Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis. *Expert Opin Pharmacother*. 2016; 17: 657-69.

19. Klimek L, Bousquet J and Price D. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. *Expert Opin Drug Saf*. 2016; 15: 117-29.

20. Prenner BM. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. *J Asthma Allergy*. 2016; 9: 135-43.

21. Dollner R, Lorentz Larsen P, Dheyauldeen S and Steinsvag S. A multicenter, prospective, noninterventional study in a Norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with MP-AzeFlu. *Allergy Rhinol (Providence)*. 2017; 8: 148-56.

22. Lipworth B, Newton J, Ram B, Small I and Schwarze J. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. *NPJ Prim Care Respir Med*. 2017; 27: 3.

23. Scadding G, Price D, El-Shanawany T, et al. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. *BMJ Open*. 2017; 7: e014777.

24. Agache I, Doros IC, Leru PM, Bucur I, Poenaru M and Sarafoleanu C. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania. *Rhinology*. 2018; 56: 33-41.

25. Bachert C, Bousquet J and Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. *Clin Transl Allergy*. 2018; 8: 25.

26. Haussler D, Sommer JU, Nastev A, et al. Influence of MP 29-02 on ciliary beat frequency in human epithelial cells in vitro. *Eur Arch Otorhinolaryngol*. 2018; 275: 1483-90.

27. Kaulsay R, Nguyen DT and Kuhl HC. Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy. *Immun Inflamm Dis*. 2018; 6: 456-64.

28. Morse E, Fujiwara RJT and Mehra S. The Association of Industry Payments to Physicians with Prescription of Brand-Name Intranasal Corticosteroids. *Otolaryngol Head Neck Surg*. 2018; 159: 442-8.

29. Roca-Ferrer J, Pujols L, Perez-Gonzalez M, et al. Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers. *Allergy Asthma Clin Immunol*. 2018; 14: 86.

30. Bjermer L, Westman M, Holmstrom M and Wickman MC. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. *Allergy Asthma Clin Immunol*. 2019; 15: 24.

31. Haahr PA, Jacobsen C and Christensen ME. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark. *Int Forum Allergy Rhinol*. 2019; 9: 388-95.

32. Ilyina NI, Edin AS, Astafieva NG, et al. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia. *Int Arch Allergy Immunol*. 2019; 178: 255-63.

33. Klimek L, Sperl A, Becker S, Mosges R and Tomazic PV. Current therapeutical strategies for allergic rhinitis. *Expert Opin Pharmacother*. 2019; 20: 83-9.

34. Scadding G, Bousquet J, Bachert C, et al. Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis. *Rhinology*. 2019; 57: 49-56.

35. Stjarne P, Strand V, Theman K and Ehnhage A. Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort. *Rhinology*. 2019; 57: 279-86.